Oxford BioMedica plc with ticker (LON:OXB) now has a potential upside of 3.3% according to Liberum Capital.
Liberum Capital set a target price of 310 GBX for the company, which when compared to the Oxford BioMedica plc share price of 300 GBX at opening today (10/10/2023) indicates a potential upside of 3.3%. Trading has ranged between 237 (52 week low) and 575 (52 week high) with an average of 229,614 shares exchanging hands daily. The market capitalisation at the time of writing is £295,166,007.
Oxford Biomedica Plc is a United Kingdom-based viral vector specialist that is primarily focused on delivering therapies to patients. The Company and its subsidiaries are engaged in viral vector delivery systems, including those based on lentivirus, adeno-associated virus (AAV) and adenovirus. It provides solutions to cell and gene therapy biotechnology and biopharma companies for their process development, analytical development and manufacturing needs. The Company has built a LentiVector platform, which is focused on a lentiviral vector delivery system. The Company is engaged in working on programs from the pre-clinical to commercial stages across a range of therapeutic areas with global partners. The Company has manufacturing, laboratory and office space across six facilities in Oxford, United Kingdom. The Company’s subsidiary, Oxford Biomedica Solutions LLC, has an AAV manufacturing facility near Boston, Massachusetts, the United States.
Oxford BioMedica plc 3.3% potential upside indicated by Liberum Capital
- Written by: Charlotte Edwards
Latest Company News
Oxford Biomedica has introduced a fast-track development and manufacturing offering for AAV and lentiviral vectors, aiming to shorten the route to GMP manufacture and help biotech clients reach clinical milestones sooner.
Oxford Biomedica plc will hold its Capital Markets Day on 2 June 2026 in London and participate in several investor conferences between March and June 2026. The company will also report FY 2025 preliminary results on 26 March 2026, followed by a virtual analyst briefing.
Oxford Biomedica has signed a new Commercial Supply Agreement with Bristol Myers Squibb for the manufacture and supply of lentiviral vectors for CAR-T programmes.
